Published : Apr-2019
No. of Pages : 75
1.1 List of Tables
1.2 List of Figures
2 Pain: Executive Summary
2.1 Substantial Unmet Needs Remain in Core Therapy Types
2.2 Highly Diversified Range of Innovative Programs in the Early Pipeline
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification
4.3 Sustained Innovation in Pain
4.4 Epidemiology for Pain
4.5 Overview for Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between Pain Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target Within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Neurotensin Receptor 1
6.3 Pipeline Programs Targeting Matrix Metalloproteinase-9/2
6.4 Pipeline Programs Targeting Beta Nerve Growth Factor
6.5 Pipeline Programs Targeting Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor
6.6 Pipeline Programs Targeting Interleukin-1 Receptor Type 2
6.7 Pipeline Programs Targeting Metabotropic Glutamate Receptor 7
6.8 Pipeline Programs Targeting Transient Receptor Potential Vanilloid Type 4
6.9 Pipeline Programs Targeting P2X Purinoceptor 7
6.10 Pipeline Programs Targeting Potassium Channel Subfamily K Member 2
7 Key Players and Deals
7.1 Overview
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 About the Authors
8.5 About GlobalData
8.6 Contact Us
8.7 Disclaimer
1.1 List of Tables
Table 1: Etiology of Chronic Pain
Table 2: Classification of Pain
Table 3: Fibromyalgia, Total Prevalent Cases, millions (N), 2013-2023
Table 4: Migraine, Total Prevalent Cases, millions (N), 2016-2026
Table 5: Painful Diabetic Neuropathy, Total Prevalent Cases, millions (N), 2016-2026
Table 6: Trigeminal Neuralgia, Total Prevalent Cases, millions (N), 2012-2022
1.2 List of Figures
Figure 1: Pain, Global Market by Molecular Target and Molecule Type, 2019
Figure 2: Pain, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 3: Pain, Global, Pipeline by Molecular Target and Stage of Development, 2019
Figure 4: Pain, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 5: Pain, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 6: Pain, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 7: Pain, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
